Pharmacopée européenne TRETINOIN (EP) R

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Tretinoin may be used as an analytical reference standard for the quantification of the analyte in dermatological formulations using high-performance liquid chromatography technique.

Biochem/physiol Actions

all−trans−Retinoic acid (ATRA) is a ligand for both the retinoic acid receptor (RAR) and the retinoid X receptor (RXR). The bound RAR and RXR act as transcription factors that regulate the growth and differentiation of both normal and malignant cells. Cytochromes P450 (CYPs) catalyze the 4-hydroxylation of ATRA. Retinoic acid primes embryonic stem cells to become neurons.

Caution

Please find SDS provided by EDQM here..

General description

This product is provided as delivered and specified by the issuing pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the authority of the issuing pharmacopoeia. For further information and support please go to the website of the issuing pharmacopoeia. Tretinoin is a medication used to treat a variety of skin conditions such as photodamaged skin, acne, etc. It is used as an anti-aging product and also as an oral treatment for leukemia.

Other Notes

Sales restrictions may apply.

Packaging

Unit quantity: 50 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.